CAMBRIDGE, Mass., Dec. 19, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and ...
A new study published today in Science Translational Medicine by researchers at The University of Texas MD Anderson Cancer Center details a therapeutic vulnerability in patients with an aggressive ...
Predictive Oncology Inc. has updated shareholders on its advancements in AI-driven drug discovery, specifically in biomarker discovery and drug repurposing, amid a growing biomarker discovery market ...
A third of patients with high-risk prostate cancer identified as biomarker-negative by an artificial intelligence (AI)–derived tool were safe to forgo long-term androgen deprivation therapy (ADT).
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)-- Results from an exploratory analysis of the TROPION-Lung01 phase 3 trial showed TROP2 as measured by quantitative continuous scoring (QCS), AstraZeneca’s ...
REHOVOT, Israel, June 27, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class oncology therapies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback